[Cited FineTest ELISA Kit] Current Research on T Cell Cancer Therapy

FineTest ELISA kit contributes to the research on T cell cancer therapy. The immunoassay is designed to measure CD122 level in supernatants.

Publication Details
Article Title: Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8+ T cell effector differentiation and anti-tumor immunity
Journal Title: Signal Transduction and Targeted Therapy
DOI: 10.1038/s41392-024-01873-6
IF: 40.8
PMID: 38918390

Abstract: CD8+ T cell immune responses are regulated by multi-layer networks, while the post-translational regulation remains largely unknown. Transmembrane ectodomain shedding is an important post-translational process orchestrating receptor expression and signal transduction through proteolytic cleavage of membrane proteins. Here, by targeting the sheddase A Disintegrin and Metalloprotease (ADAM)17, we defined a post-translational regulatory mechanism mediated by the ectodomain shedding in CD8+ T cells. Transcriptomic and proteomic analysis revealed the involvement of post-translational regulation in CD8+ T cells. T cell-specific deletion of ADAM17 led to a dramatic increase in effector CD8+ T cell differentiation and enhanced cytolytic effects to eliminate pathogens and tumors. Mechanistically, ADAM17 regulated CD8+ T cells through cleavage of membrane CD122. ADAM17 inhibition led to elevated CD122 expression and enhanced response to IL-2 and IL-15 stimulation in both mouse and human CD8+ T cells. Intriguingly, inhibition of ADAM17 in CD8+ T cells improved the efficacy of chimeric antigen receptor (CAR) T cells in solid tumors. Our findings reveal a critical post-translational regulation in CD8+ T cells, providing a potential therapeutic strategy of targeting ADAM17 for effective anti-tumor immunity.

Keywords: T Cell Cancer Therapy, Tumour Immunology, Lymphocytes, Cell Differentiation

Immunoassay

Validated Image

Figure Source: Signal Transduct Target Ther. 2024 Jun 26;9(1):152. doi: 10.1038/s41392-024-01873-6.